Search Results for "miller"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for miller. Results 1 to 8 of 8 total matches.
Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
. Genes (Basel) 2020; 11:450.
3. JL Miller et al. Diazoxide choline extended-release tablet in
people ...
The FDA has approved diazoxide choline extended-release
tablets (Vykat XR – Soleno Therapeutics) for
treatment of hyperphagia in patients ≥4 years old
with Prader-Willi syndrome. Diazoxide choline is the
first drug to be approved in the US for this indication.
Diazoxide oral suspension (Proglycem) has been
available for years for management of symptomatic
hypoglycemia.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):e72-3 doi:10.58347/tml.2025.1727e | Show Introduction Hide Introduction
Tofersen (Qalsody) for ALS
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
from those with placebo.
Serious neurologic adverse events have occurred.
1. TM Miller et al. Trial ...
Tofersen (Qalsody – Biogen), an intrathecally
administered antisense oligonucleotide, has received
accelerated approval from the FDA for treatment of
amyotrophic lateral sclerosis (ALS) in adults who
have a mutation in the superoxide dismutase 1
(SOD1) gene. About 2% of patients with ALS have
mutations in the SOD1 gene. Tofersen is the first drug
to be approved in the US that targets a genetic cause
of ALS. Accelerated approval of the drug was based
on the surrogate endpoint of a reduction in plasma
neurofilament light chain, which is considered likely
to predict clinical...
Med Lett Drugs Ther. 2023 Jul 24;65(1681):113-4 doi:10.58347/tml.2023.1681a | Show Introduction Hide Introduction
In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
after vaccination
with Arexvy and one case each of GBS and Miller
Fisher syndrome (a variant of GBS ...
The FDA has required a new warning in the labels of the
recombinant respiratory syncytial virus (RSV) vaccines
Arexvy (GSK) and Abrysvo (Pfizer) about an increased
risk of Guillain-Barré syndrome (GBS) within 42 days
of administration of either vaccine. Both vaccines
are FDA-approved to prevent lower respiratory tract
disease (LRTD) caused by RSV in adults.Abrysvo is
also approved for use in pregnant women at 32-36
weeks' gestation to prevent RSV-associated LRTD in
their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):31-2 doi:10.58347/tml.2025.1722d | Show Introduction Hide Introduction
Relyvrio for ALS
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
J Med 2017; 377:162.
4. RG Miller et al. Riluzole for amyotrophic lateral sclerosis
(ALS)/motor ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose
combination of sodium phenylbutyrate and
taurursodiol, for treatment of amyotrophic lateral
sclerosis (ALS). Sodium phenylbutyrate (Buphenyl,
and others) has been available by prescription
for years for treatment of urea cycle disorders.
Taurursodiol (tauroursodeoxycholic acid), a derivative
of ursodiol, is an over-the-counter bile acid
supplement claimed to have neuroprotective
benefits. Relyvrio is the third drug to be approved
in the US for treatment of ALS; riluzole (Rilutek, and
others) and edaravone (Radicava, Radicava...
Drugs for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
Lett Drugs Ther 2017; 59:97.
32. PD Miller et al. Bone mineral density response rates are
greater ...
Pharmacologic treatment is recommended for
postmenopausal women who have bone density
T-scores (standard deviations from normal mean
values in the spine, femoral neck, total hip, or distal
radius) of -2.5 or below, T-scores between -1.0 and
-2.5 with a history of fragility (low-trauma) fracture
of the hip or spine, or T-scores between -1.0 and
-2.5 with a FRAX 10-year probability of ≥3% for hip
fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12 doi:10.58347/tml.2024.1706a | Show Introduction Hide Introduction
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
, and one case each of GBS and Miller Fisher syndrome (a variant of GBS) 7 and 8 days, respectively, after ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Insect Repellents
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021 (Issue 1628)
Miller et al. Tick bite protection with permethrin-treated
summer-weight clothing. J Med Entomol 2011 ...
The Centers for Disease Control and Prevention
(CDC) and the Environmental Protection Agency
(EPA) recommend using insect repellents to prevent
infections transmitted by mosquitoes and ticks.
Insect repellents applied to exposed skin should be
used in conjunction with other preventive measures
such as wearing pants and long-sleeved shirts and
avoiding outdoor activities during peak mosquito-biting
times. Mosquitoes can transmit diseasecausing
pathogens, including Zika, chikungunya,
dengue, West Nile, eastern equine encephalitis, and
yellow fever viruses, and the malaria parasite....
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
. Cochrane Database Syst Rev 2014 Dec; 2014
(12):CD009281.
6. M Miller et al. Prescription opioid duration ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.